An association study of IL2RA polymorphisms with cerebral palsy in a Chinese population

doi:10.21203/rs.3.rs-1657207/v1

Download PDF

Research Article

An association study of IL2RA polymorphisms with cerebral palsy in a Chinese population

https://doi.org/10.21203/rs.3.rs-1657207/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Background

Cerebral palsy (CP), the most common physical disability of childhood, is a nonprogressive movement disorder syndrome. Eighty percent of cases are considered idiopathic without a clear cause. Evidence has shown that cytokine abnormalities are widely thought to contribute to CP.

Methods

An association between IL2RA (rs12244380, rs2025345, rs12722561, rs4749926, rs2104286 and rs706778) and CP was investigated using a case-control method based on 782 CP cases and 778 controls. The allele, genotype and haplotype frequencies of SNPs were assessed using the SHEsis program. Subgroup analyses based on complications and clinical subtypes were also conducted.

Results

Globally, no differences in genotype or allele frequencies for any SNPs remained significant after Bonferroni correction between patients and controls, except rs706778, which deviated from Hardy-Weinberg equilibrium and was excluded from further analyses. However, subgroup analysis revealed a significant association of rs2025345 with spastic tetraplegia (P genotype = 0.048 after correction) and rs12722561 with CP accompanied by global developmental delay (P allele = 0.045 after correction), even after Bonferroni correction.

Conclusions

These findings indicated that genetic variations in IL2RA are significantly associated with CP susceptibility in the Chinese Han population, suggesting that IL2RA is likely involved in the pathogenesis of CP. Further investigation with a larger sample size in a multiethnic population is needed to confirm the association.

association study

IL2RA

cerebral palsy

Chinese population

gene polymorphism

Cerebral palsy (CP) is a nonprogressive movement disorder caused by brain damage occurring in the developing fetus or infant [1, 2]. It is a group of permanent disorders that can affect the development of sports and lead to restricted activities [3]. CP is one of the most common physical disability diseases in children, with an incidence of 1.5–2.5/1,000 live births [4]. Although some studies have pointed out that risk factors, such as intrauterine infection, hypoxic-ischemia insults, and central nervous system infections, can result in CP [5, 6], 80% of cases are considered idiopathic without a clear cause [7]. It has been reported that CP children are prone to have congenital anomalies, the incidence is higher in identical twins than in fraternal twins, and the risk of CP is higher in consanguineous families than nonconsanguineous families [8], suggesting that genetic factors may play an important role in the etiology of CP. Moreover, genes such as NOS1, OLIG2, ATG5, ATG7 and IL-6 have been significantly associated with susceptibility to CP [9–12].

CP is linked to immune dysfunction, including altered serum and cerebrospinal fluid cytokine profiles and aberrant cell-mediated immune responses [13]. Inflammation is one etiologic component of brain white matter damage acquired during early development that gives rise to CP [14, 15]. In addition, cytokines, such as interleukins and interferons, are a group of small and secreted proteins that can mediate normal and continuous signal transduction between nonimmune tissue cells, including the central nervous system (CNS) [16]. Cytokines are of particular importance during neural development and function at all stages and are associated with CP and other neurodevelopmental disorders (NDDs). Magalhaes et al. analyzed the relationship between inflammatory molecules and neurodevelopment and found that higher circulating levels of IL-1β, IL-6, TNF and CXCL8/IL-8 were associated with neurological abnormalities in CP children [17]. Furthermore, studies have reported that IL-23R, IL-8 and IL-6 gene polymorphisms are related to CP in the Chinese population[18–20].

Interleukin-2 (IL-2), the first cytokine to be molecularly cloned, is a typical alpha helix cytokine that binds to and transmits signals through the IL-2 receptor (IL2R) complex, which consists of 3 different subunits, IL2RA (CD25), IL2RB (CD122), and IL2RG (CD132) [21, 22]. Previous studies have proven that the IL-2/IL2R complex signaling pathway plays a key role in the proliferation of T cells and the generation of effector and memory cells to promote immune responses. Furthermore, the IL-2/IL2R complex signaling pathway can promote the generation, survival, and functional activity of Treg cells to control immune responses and maintain self-tolerance [23]. Damaging mutations disrupting this pathway can cause severe forms of Mendelian immune dysregulation [22, 23]. IL2RA forms the largest of the three subunit interfaces, which, together with the high abundance of charge-charge interactions, correlates well with the rapid association rate and high-affinity interaction of IL2RA with IL-2 at the cell surface [24, 25]. IL2RA deficiency can result in human immune-mediated diseases [26–28].

Based on the above findings, we speculate that IL2RA may be associated with susceptibility to CP. However, it remains unknown whether IL2RA is associated with CP. Therefore, we used a case-control study to explore the possible association of IL2RA with CP, which will provide genetic evidence for the role of IL2RA in the etiology of CP and its related potential mechanisms.

Participants

In our study, 782 children with CP and 778 healthy controls were recruited from the centers for CP rehabilitation and Child Health Care Departments in the Third Affiliated Hospital of Zhengzhou University, Zhengzhou Children’s Hospital. This study was approved by the Ethics Committee of Zhengzhou University and the Medical Academy of Henan Province in accordance with the principles of the Declaration of Helsinki. Statements of informed consent were obtained from the guardians of all children after full explanation of the procedure. The case group consisted of 542 males (69.3%) and 240 females (30.7%), and the mean age was 18.5 ± 15.4 months. The control group consisted of 778 healthy children, including 520 males (66.8%) and 258 females (33.2%), and the mean age was 19.3 ± 16.8 months (Table 1)

Table 1

Clinical characteristics of all participants
Characteristic	CP cases (n = 782)	Controls (n = 778)
Sex (male: female)	542:240	520:258
Preterm (< 37weeks)	47	10
Low Birth Weight (< 2500 g)	40	2
Birth Asphyxia	229	13
Type of CP
Spastic CP	522	NA
CP with quadriplegia	284	NA
CP with diplegia	126	NA
Complications
CP with NE	310	NA
CP with GDD	299	NA
Maternal factors
PIH	26	NA
CP cerebral palsy, GDD Global developmental delay, NE neonatal encephalopathy, PIH pregnancy-induced hypertension.

CP diagnosis, classification and exclusion criteria

In the case group, children diagnosed with congenital metabolic diseases and myopathy as well as children with a family history of nervous system diseases were excluded. Pediatric rehabilitation specialists ensured CP diagnosis using standard criteria related to nonprogressive disorders of movement control and posture [1]. Every participant received a detailed clinical evaluation with comprehensive pretest counseling.

Clinical information, including demographic variables (such as sex, gestational age, mode of delivery, singletons or twins), known risk factors (such as pregnancy-induced hypertension (PIH), perinatal asphyxia, threatened premature labor), CP complications (such as global developmental delay, intellectual disability) and neonatal complications, were all recorded if available.

Quadriplegia, one subtype of CP, is classified by the number and distribution of the impaired limbs [29, 30]. Quadriplegia was diagnosed when both the upper and lower limbs of the patients were paralyzed. Global developmental delay (GDD) diagnosis was limited to individuals under five years old when the achievement of motor or mental milestones in the domains of development of a child, including motor skills, speech and language, cognitive skills, and social and emotional skills, were delayed.

Genotyping and statistical analysis

Peripheral blood samples were obtained from the participants for genomic DNA extraction. According to the single nucleotide polymorphism (SNP) location in IL2RA, a minor allele frequency (MAF) > 0.1 and potential function, six SNPs (rs12244380, rs2025345, rs12722561, rs4749926, rs2104286 and rs706778) were selected as candidates and genotyped by the MassARRAY system (Shanghai Perchant Biotechnology Co., Ltd. synthesized primers and probes).

Statistical analysis was performed with SHEsis, an online program (http://analysis.bio-x.cn/) that can test Hardy-Weinberg equilibrium (HWE) and linkage disequilibrium (LD) and calculate allele frequencies, genotype frequencies and haplotype frequencies in the case and control groups. The P values were two-tailed, and P < 0.05 was considered significant. The odds ratio (OR) and its 95% confidence interval (CI) were also calculated. The Bonferroni correction was applied to account for multiple testing on each individual SNP and haplotype. G*power 3.1 software was used to evaluate statistical efficacy.

Overall analysis

Power calculations analysis showed that the sample size in this study had > 85% power to detect a significant association with an effect size index of 0.1 (α < 0.05). Except for rs706778 (p = 0.042), the genotype distribution of the selected SNPs did not deviate from HWE in the control population (p > 0.05). Therefore, rs706778 was excluded from further testing. For the other 5 SNPs, rs12244380, rs2025345, rs12722561, rs4749926 and rs2104286, the allele frequency of rs12722561 (P = 0.025) was different between all CP patients and the control group, but the difference disappeared after Bonferroni correction. There were no significant differences in the allele or genotype frequencies of rs12244380, rs2025345, rs4749926 and rs2104286 between CP cases and controls (Table 2).

Haplotype analysis is a powerful strategy to determine whether SNPs have greater predictive value when analyzed together. These polymorphisms, rs2025345, rs12722561 and rs4749926, exhibit a strong LD (D’> 0.85) and form four principal haplotypes (ACA, ACG, ATG and GCA). The ATG haplotype was associated with CP (P = 0.026), but the difference disappeared after correction (Table 3).

Table 2

Genotype and allele frequencies of SNPs in *IL2RA* between CP and controls
Group	Allele frequency		p value	OR [95% CI]	Genotype frequency			p value
rs12244380	A	G			A/A	A/G	G/G
CP	1243 (0.874)	179 (0.126)	0.401	1.098 [0.883 ~ 1.364]	543 (0.764)	157 (0.221)	11 (0.015)	0.628
Control	1240 (0.864)	196 (0.136)	0.401	1.098 [0.883 ~ 1.364]	533 (0.742)	174 (0.242)	11 (0.015)	0.628
rs2025345	A	G			A/A	A/G	G/G
CP	907 (0.627)	539 (0.373)	0.341	0.929 [0.798 ~ 1.081]	275 (0.380)	357 (0.494)	91 (0.126)	0.227
Control	915 (0.644)	505 (0.356)	0.341	0.929 [0.798 ~ 1.081]	298 (0.420)	319 (0.449)	93 (0.131)	0.227
rs12722561	C	T			C/C	C/T	T/T
CP	1307 (0.887)	167 (0.113)	0.025^a	1.284 [1.031 ~ 1.599]	579 (0.786)	149 (0.202)	9 (0.012)	0.080
Control	1225 (0.859)	201 (0.141)	0.025^a	1.284 [1.031 ~ 1.599]	525 (0.736)	175 (0.245)	13 (0.018)	0.080
rs4749926	A	G			A/A	A/G	G/G
CP	595 (0.395)	911 (0.605)	0.981	1.002 [0.865 ~ 1.160]	105 (0.139)	385 (0.511)	263 (0.349)	0.983
Control	592 (0.395)	908 (0.605)	0.981	1.002 [0.865 ~ 1.160]	106 (0.141)	380 (0.507)	264 (0.352)	0.983
rs2104286	C	T			C/C	C/T	T/T
CP	172 (0.116)	1312 (0.884)	0.127	0.844 [0.679 ~ 1.050]	3 (0.004)	166 (0.224)	573 (0.772)	0.166
Control	200 (0.134)	1288 (0.866)	0.127	0.844 [0.679 ~ 1.050]	8 (0.011)	184 (0.247)	552 (0.742)	0.166
OR: odds ratio; CI: confidence interval. P value after Bonfferoni: a: 0.126.

Table 3

Haplotype analysis of rs2025345-rs12722561-rs4749926
Haplotype	Case (frequency)	Control (frequency)	p-value	OR [95% CI]
ACA	19.77(0.038)	68.12(0.050)	0.231	0.732 [0.439 ~ 1.221]
ACG	253.28(0.483)	619.74(0.456)	0.410	1.090 [0.888 ~ 1.336]
ATG	48.32(0.092)	173.26(0.128)	0.026	0.684 [0.488 ~ 0.957]
GCA	191.58(0.366)	450.93(0.332)	0.231	1.138 [0.921 ~ 1.407]

Subgroup analysis

CP is a syndrome with strong phenotypic and etiological heterogeneity. The genetic diagnosis rate of different clinical subtypes of CP is inconsistent, suggesting that different types of CP may have different genetic etiologies. Then, we conducted a subgroup analysis to explore the association of different CP types with IL2RA genetic variants. The results indicated that the association of spastic tetraplegia with rs2025345 (OR = 0.868, 95% CI = 0.706 ~ 1.066, P genotype = 0.0097) and the association of CP + GDD with rs12722561 (OR = 1.518, 95% CI = 1.107 ~ 2.082, P allele = 0.0091) were both significant, even after Bonferroni correction. Moreover, the analysis of the other three SNPs in CP types and controls revealed a nonsignificant difference in allelic and genotypic distributions (Tables 4 & 5).

The analysis of the association between IL2RA and various risk factors detected a significant influence on CP by the interactions between genotype distribution in rs12244380 and pregnancy-induced hypertension; even after Bonferroni correction, the association between them was still significant (OR = 0.531, 95% CI = 0.266 ~ 1.059, P = 0.0005) (Table 6). However, the proportions of pregnancy-induced hypertension exposure in CP cases and controls presented a large difference, which may have weakened the feasibility of the P value. In addition, rs12722561 presented a significant association with CP + asphyxia, CP + neonatal encephalopathy (NE) and CP + intracranial hemorrhage, but the significance disappeared after Bonferroni correction.

Table 4

Allele and genotype frequencies of *IL2RA* in CP with spastic tetraplegia and controls
Group	Allele frequency		p value	OR [95% CI]	Genotype frequency			p value
rs12244380	A	G			A/A	A/G	G/G
CP	456 (0.857)	76 (0.143)	0.716	0.948 [0.713 ~ 1.262]	198 (0.744)	60 (0.226)	8 (0.030)	0.298
Control	1240 (0.864)	196 (0.136)	0.716	0.948 [0.713 ~ 1.262]	533 (0.742)	174 (0.242)	11 (0.015)	0.298
rs2025345	A	G			A/A	A/G	G/G
CP	324 (0.611)	206 (0.389)	0.177	0.868 [0.707 ~ 1.066]	88 (0.332)	148 (0.558)	29 (0.109)	0.0097^a
Control	915 (0.644)	505 (0.356)	0.177	0.868 [0.707 ~ 1.066]	298 (0.420)	319 (0.449)	93 (0.131)	0.0097^a
rs12722561	C	T			C/C	C/T	T/T
CP	487 (0.892)	59 (0.108)	0.053	1.354 [0.995 ~ 1.844]	216 (0.791)	55 (0.201)	2 (0.007)	0.137
Control	1225 (0.859)	201 (0.141)	0.053	1.354 [0.995 ~ 1.844]	525 (0.736)	175 (0.245)	13 (0.018)	0.137
rs4749926	A	G			A/A	A/G	G/G
CP	227 (0.416)	319 (0.584)	0.389	1.091 [0.894 ~ 1.332]	40 (0.147)	147 (0.538)	86 (0.315)	0.540
Control	592 (0.395)	908 (0.605)	0.389	1.091 [0.894 ~ 1.332]	106 (0.141)	380 (0.507)	264 (0.352)	0.540
rs2104286	C	T			C/C	C/T	T/T
CP	70 (0.126)	484 (0.874)	0.633	0.931 [0.696 ~ 1.247]	1 (0.004)	68 (0.245)	208 (0.751)	0.551
Control	200 (0.134)	1288 (0.866)	0.633	0.931 [0.696 ~ 1.247]	8 (0.011)	184 (0.247)	552 (0.742)	0.551
P value after Bonfferoni a: 0.048.

Table 5

Allele and genotype frequencies of *IL2RA* in CP with GDD and controls
Group	Allele frequency		p value	OR [95% CI]	Genotype frequency			p value
rs12244380	A	G			A/A	A/G	G/G
CP	480 (0.873)	70 (0.127)	0.589	1.084 [0.809 ~ 1.452]	208 (0.756)	64 (0.233)	3 (0.011)	0.817
Control	1240 (0.864)	196 (0.136)	0.589	1.084 [0.809 ~ 1.452]	533 (0.742)	174 (0.242)	11 (0.015)	0.817
rs2025345	A	G			A/A	A/G	G/G
CP	342 (0.622)	208 (0.378)	0.350	0.907 [0.740 ~ 1.113]	105 (0.382)	132 (0.480)	38 (0.138)	0.554
Control	915 (0.644)	505 (0.356)	0.350	0.907 [0.740 ~ 1.113]	298 (0.420)	319 (0.449)	93 (0.131)	0.554
rs12722561	C	T			C/C	C/T	T/T
CP	509 (0.902)	55 (0.098)	0.0091^a	1.519 [1.107 ~ 2.082]	230 (0.816)	49 (0.174)	3 (0.011)	0.030^b
Control	1225 (0.859)	201 (0.141)	0.0091^a	1.519 [1.107 ~ 2.082]	525 (0.736)	175 (0.245)	13 (0.018)	0.030^b
rs4749926	A	G			A/A	A/G	G/G
CP	229 (0.399)	345 (0.601)	0.858	1.018 [0.836 ~ 1.239]	41 (0.143)	147 (0.512)	99 (0.345)	0.978
Control	592 (0.395)	908 (0.605)	0.858	1.018 [0.836 ~ 1.239]	106 (0.141)	380 (0.507)	264 (0.352)	0.978
rs2104286	C	T			C/C	C/T	T/T
CP	62 (0.110)	502 (0.890)	0.138	0.795 [0.587 ~ 1.077]	1 (0.004)	60 (0.213)	221 (0.784)	0.258
Control	200 (0.134)	1288 (0.866)	0.138	0.795 [0.587 ~ 1.077]	8 (0.011)	184 (0.247)	552 (0.742)	0.258
P value after Bonfferoni: a:0.045; b:0.15.

Table 6

Allele and genotype frequencies of *IL2RA* in CP with pregnancy-induced hypertension and controls
Group	Allele frequency		p value	OR [95% CI]	Genotype frequency			p value
rs12244380	A	G			A/A	A/G	G/G
CP	37 (0.771)	11 (0.229)	0.068	0.531 [0.266 ~ 1.059]	16 (0.667)	5 (0.208)	3 (0.125)	0.0005^a
Control	1240 (0.864)	196 (0.136)	0.068	0.531 [0.266 ~ 1.059]	533 (0.742)	174 (0.242)	11 (0.015)	0.0005^a
rs2025345	A	G			A/A	A/G	G/G
CP	30 (0.625)	18 (0.375)	0.783	0.920 [0.0.508 ~ 1.667]	8 (0.333)	14 (0.583)	2 (0.083)	0.418
Control	915 (0.644)	505 (0.356)	0.783	0.920 [0.0.508 ~ 1.667]	298 (0.420)	319 (0.449)	93 (0.131)	0.418
rs12722561	C	T			C/C	C/T	T/T
CP	37 (0.771)	11 (0.229)	0.087	0.552 [0.277 ~ 1.100]	15 (0.625)	7 (0.292)	2 (0.083)	0.066
Control	1225 (0.859)	201 (0.141)	0.087	0.552 [0.277 ~ 1.100]	525 (0.736)	175 (0.245)	13 (0.018)	0.066
rs4749926	A	G			A/A	A/G	G/G
CP	22 (0.440)	28 (0.560)	0.519	1.205 [0.683 ~ 2.127]	5 (0.200)	12 (0.480)	8 (0.320)	0.710
Control	592 (0.395)	908 (0.605)	0.519	1.205 [0.683 ~ 2.127]	106 (0.141)	380 (0.507)	264 (0.352)	0.710
rs2104286	C	T			C/C	C/T	T/T
CP	8 (0.167)	40 (0.833)	0.520	1.288 [0.594 ~ 2.792]	0 (0.000)	8 (0.333)	16 (0.667)	0.570
Control	200 (0.134)	1288 (0.866)	0.520	1.288 [0.594 ~ 2.792]	8 (0.011)	184 (0.247)	552 (0.742)	0.570
P value after Bonfferoni: a:0.0026.

CP is the most common physical disability of childhood and is a heterogeneous condition resulting from damage to the developing brain [31]. CP has no curative therapy and few disease-modifying interventions [32]. Earlier and accurate diagnosis of CP has become highly desirable because it allows earlier initiation of treatments that may improve long-term outcomes during periods of rapid brain growth and neuroplasticity, which suggests the importance of uncovering the etiology of CP[33]. However, these known CP causes, such as periventricular leukomalacia (PVL), NE, infarct, and premature delivery, account for only a minority of the total cases [18]. The pathogenesis of CP is largely unknown and needs further study.

Cytokines coordinate the host response to infection and mediate normal, ongoing signaling between cells of nonimmune tissues, including the CNS [16]. Cytokines can profoundly impact fetal neurodevelopment in response to maternal infection or prenatal hypoxia [34]. CP has been linked to early life immune activation and inflammation [35, 36], and several cytokines, including IL-6, IL-8, IL-10, IL-17 and IL-23R, have been proven to be related to CP [18, 33, 37, 38]. IL-2 is a pleiotropic cytokine produced after antigen activation. IL-2 can promote CD8⁺ T cell and natural killer cells cytolytic activity, modulate T-cell differentiation programs in response to antigens and control the development and maintenance of Treg cells to mediate immune responses and maintain self-tolerance by the IL-2/IL2R complex signaling pathway [39]. IL2RA provides a higher affinity to the IL2R complex and a more stable state through which to transmit signals. Studies have shown that the expression of the anti-inflammatory cytokine IL-2 is decreased in infants with CP [40, 41], which implies that the IL2/IL2R complex pathway is related to CP. Here, we first investigated the relationship between CP and IL2RA by a case-control study in Han Chinese individuals and found that IL2RA was associated with an increased risk of CP.

Several kinds of immune-activated cells have been shown to secrete IL-2, including T cells, natural killer cells, dendritic cells (DCs) and mast cells [42]. During immune activation, IL-2 expression increases rapidly. Activated DCs secrete low levels of IL-2 as an early source, thereby stimulating T cell activation [43]. Activated T cells (including CD4⁺ and CD8⁺ T cells) begin to secrete large amounts of IL-2 for their own use and stimulate adjacent IL2R⁺ cells by paracrine signaling [39, 44, 45]. After IL-2 binds to the IL2R complex, signal transduction occurs through three main pathways: (i) Janus kinase (JAK)-signal transducer and activator of transcription (STAT), (ii) the phosphoinositide 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR)-p70 S6 kinase pathway and (iii) mitogen-activated protein kinase (MAPK). Phosphorylated STAT5A and STAT5B then oligomerize to form STAT5 dimers and tetramers before undergoing nuclear translocation, where they bind to key target genes (including IL2RA) responsible for cell activation, differentiation, and proliferation, while mTOR and MAPK promote cell growth and survival [22, 39, 44]. It is reasonable to hypothesize that IL2/IL2R complex signaling pathways are disturbed by functional genetic variants, immune cells are unable to proliferate and differentiate normally and the immune system cannot respond optimally to antigen stimulation, causing damage to the developing brain (CP).

Previous studies have shown that disruption of IL2/IL2R complex signaling pathways can lead to adverse cerebral events. In IL-2 knockout (IL-2 KO) mice, brain IL2R complexes are enriched in hippocampal formation, and loss of IL-2 results in cytoarchitectural alterations in the hippocampus and septum. These alterations include decreased cholinergic somata in the medial septum/vertical limb of the diagonal band of Broca (MS/vDB) and decreased distance across the infrapyramidal (IP) granule cell layer (GCL) of the dentate gyrus (DG) [46]. The deletion of IL-2 alters the neuroimmunological status of the mouse hippocampus through dysregulation of cytokines produced by CNS cells [47]. A study in 2015 suggested that complex interactions between IL2 deficiency in the brain and the immune system may modify brain processes involved in different modalities of learning and memory [48]. In this study, we analyzed the correlation between five SNPs of IL2RA and CP and finally ascertained the association of IL2RA with CP. The results of our study showed that there might be an association between IL2RA and susceptibility to CP, implying that SNPs in the IL2RA gene might be involved in the occurrence and development of CP.

Our study has several limitations. First, our study was based on a single gene for susceptibility to CP. Given the genetic heterogeneity and gene-gene interactions related to CP etiology, other candidate genes that are part of the IL2/IL2R complex signaling pathway should also be analyzed. Second, we were unable to examine IL2RA protein expression in the brains of the subjects in the current study. Future studies are encouraged to measure inflammatory cytokine alterations in the brain. Third, although our study demonstrated an association between IL2RA and CP, further functional studies are necessary to verify the results.

We examined the influence of 6 SNPs (rs12244380, rs2025345, rs12722561, rs4749926, rs2104286 and rs706778) in IL2RA on susceptibility to CP and identified IL2RA as a risk gene for CP. To our knowledge, the role of genetic variation in IL2RA in susceptibility to CP has not been investigated before. The full effect of the IL2RA gene on CP cannot be revealed by the analysis of a limited number of SNPs. Future studies on a larger number of samples and on different ethnic groups will be required to better understand the contribution of IL2RA variants to the risk of CP.

CP: Cerebral palsy; SNP: Single nucleotide polymorphism; CNS: central nervous system; OR: Odds ratio; CI: Confidence interval; HWE: Hardy-weinberg equilibrium; MAF: Minor allele frequency; GDD: Global developmental delay; NE: neonatal encephalopathy; PIH: pregnancy-induced hypertension.

Acknowledgments

We thank all participants involved in this study and all authors.

Funding

This work was supported by the Shanghai Municipal Commission of Science and Technology Research Project (19JC1411001), the National Natural Science Foundation of China (31972880, 32170615, 31611130035, 31371274), the National Key Research and Development Plan for Stem Cell and Transformation Research (2017YFA0104202), the collaborative innovation center project construction for Shanghai women and children's health (No. 15GWZK0401).

Availability of data and materials

The authors are unable to share detailed clinical data due to full anonymization of the data is very difficult. But the datasets analyzed and generated during the study are available from the corresponding author on reasonable request.

Contributions

QX and CZ conceived and designed the study. YX, DB, JS, LX, ML, XZ, DZ and XW recruited subjects and sorted out clinical information. YQ, YW, JZ, YS, YC, TW and JD performed the laboratory work. YQ, YW and YX performed all data and statistical analysis. YQ and YW drafted the manuscript. QX and CZ revised the manuscript critically for important intellectual content. All authors contributed and critically reviewed the final version of the manuscript. All authors have read and approved the final manuscript.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Zhengzhou University and the Medical Academy of Henan Province in accordance with the principles of the Declaration of Helsinki. Statements of informed consent were obtained from the guardians of all children after full explanation of the procedure.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, Dan B, Jacobsson B: A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl 2007, 109:8-14.
Vitrikas K, Dalton H, Breish D: Cerebral Palsy: An Overview. Am Fam Physician 2020, 101(4):213-220.
Maisonneuve E, Lorthe E, Torchin H, Delorme P, Devisme L, L'Helias LF, Marret S, Subtil D, Bodeau-Livinec F, Pierrat V et al: Association of Chorioamnionitis with Cerebral Palsy at Two Years after Spontaneous Very Preterm Birth: The EPIPAGE-2 Cohort Study. J Pediatr 2020, 222:71-78 e76.
Oskoui M, Coutinho F, Dykeman J, Jette N, Pringsheim T: An update on the prevalence of cerebral palsy: a systematic review and meta-analysis. Dev Med Child Neurol 2013, 55(6):509-519.
MacLennan AH, Thompson SC, Gecz J: Cerebral palsy: causes, pathways, and the role of genetic variants. Am J Obstet Gynecol 2015, 213(6):779-788.
Nelson KB: Causative factors in cerebral palsy. Clin Obstet Gynecol 2008, 51(4):749-762.
Novak I, Morgan C, Adde L, Blackman J, Boyd RN, Brunstrom-Hernandez J, Cioni G, Damiano D, Darrah J, Eliasson AC et al: Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment. JAMA Pediatr 2017, 171(9):897-907.
Moreno-De-Luca A, Ledbetter DH, Martin CL: Genetic insights into the causes and classification of cerebral palsies. Lancet Neurol 2012, 11(3):283-292.
Xu J, Xia L, Shang Q, Du J, Zhu D, Wang Y, Bi D, Song J, Ma C, Gao C et al: A Variant of the Autophagy-Related 5 Gene Is Associated with Child Cerebral Palsy. Front Cell Neurosci 2017, 11:407.
Yu T, Xia L, Bi D, Wang Y, Shang Q, Zhu D, Song J, Wang Y, Wang X, Zhu C et al: Association of NOS1 gene polymorphisms with cerebral palsy in a Han Chinese population: a case-control study. BMC Med Genomics 2018, 11(1):56.
Sun L, Xia L, Wang M, Zhu D, Wang Y, Bi D, Song J, Ma C, Gao C, Zhang X et al: Variants of the OLIG2 Gene are Associated with Cerebral Palsy in Chinese Han Infants with Hypoxic-Ischemic Encephalopathy. Neuromolecular Med 2019, 21(1):75-84.
Xia L, Xu J, Song J, Xu Y, Zhang B, Gao C, Zhu D, Zhou C, Bi D, Wang Y et al: Autophagy-Related Gene 7 Polymorphisms and Cerebral Palsy in Chinese Infants. Front Cell Neurosci 2019, 13:494.
Zareen Z, Strickland T, Fallah L, McEneaney V, Kelly L, McDonald D, Molloy EJ: Cytokine dysregulation in children with cerebral palsy. Dev Med Child Neurol 2021, 63(4):407-412.
Stolp HB, Ek CJ, Johansson PA, Dziegielewska KM, Bethge N, Wheaton BJ, Potter AM, Saunders NR: Factors involved in inflammation-induced developmental white matter damage. Neurosci Lett 2009, 451(3):232-236.
Kannan S, Saadani-Makki F, Muzik O, Chakraborty P, Mangner TJ, Janisse J, Romero R, Chugani DC: Microglial activation in perinatal rabbit brain induced by intrauterine inflammation: detection with 11C-(R)-PK11195 and small-animal PET. J Nucl Med 2007, 48(6):946-954.
Deverman BE, Patterson PH: Cytokines and CNS development. Neuron 2009, 64(1):61-78.
Magalhaes RC, Moreira JM, Lauar AO, da Silva AAS, Teixeira AL, ACS ES: Inflammatory biomarkers in children with cerebral palsy: A systematic review. Res Dev Disabil 2019, 95:103508.
Wang Y, Xu Y, Fan Y, Bi D, Song J, Xia L, Shang Q, Gao C, Zhang X, Zhu D et al: The Association Study of IL-23R Polymorphisms With Cerebral Palsy in Chinese Population. Front Neurosci 2020, 14:590098.
Chen M, Li T, Lin S, Bi D, Zhu D, Shang Q, Ma C, Wang H, Wang L, Zhang Y et al: Association of Interleukin 6 gene polymorphisms with genetic susceptibilities to spastic tetraplegia in males: a case-control study. Cytokine 2013, 61(3):826-830.
Bi D, Chen M, Zhang X, Wang H, Xia L, Shang Q, Li T, Zhu D, Blomgren K, He L et al: The association between sex-related interleukin-6 gene polymorphisms and the risk for cerebral palsy. J Neuroinflammation 2014, 11:100.
Nelson BH, Willerford DM: Biology of the interleukin-2 receptor. Adv Immunol 1998, 70:1-81.
Damoiseaux J: The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor. Clin Immunol 2020, 218:108515.
Abbas AK, Trotta E, D RS, Marson A, Bluestone JA: Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol 2018, 3(25).
Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA: Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A 2006, 103(8):2788-2793.
Wang HM, Smith KA: The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med 1987, 166(4):1055-1069.
Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW: CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol 2007, 119(2):482-487.
Goudy K, Aydin D, Barzaghi F, Gambineri E, Vignoli M, Ciullini Mannurita S, Doglioni C, Ponzoni M, Cicalese MP, Assanelli A et al: Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immunol 2013, 146(3):248-261.
Sharfe N, Dadi HK, Shahar M, Roifman CM: Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl Acad Sci U S A 1997, 94(7):3168-3171.
Shavelle RM, Straus DJ, Day SM: Comparison of survival in cerebral palsy between countries. Dev Med Child Neurol 2001, 43(8):574-574.
Gorter JW, Rosenbaum PL, Hanna SE, Palisano RJ, Bartlett DJ, Russell DJ, Walter SD, Raina P, Galuppi BE, Wood E: Limb distribution, motor impairment, and functional classification of cerebral palsy. Dev Med Child Neurol 2004, 46(7):461-467.
Morgan C, Fahey M, Roy B, Novak I: Diagnosing cerebral palsy in full-term infants. J Paediatr Child Health 2018, 54(10):1159-1164.
Wimalasundera N, Stevenson VL: Cerebral palsy. Pract Neurol 2016, 16(3):184-194.
Michael-Asalu A, Taylor G, Campbell H, Lelea LL, Kirby RS: Cerebral Palsy: Diagnosis, Epidemiology, Genetics, and Clinical Update. Adv Pediatr 2019, 66:189-208.
Brandenburg JE, Fogarty MJ, Sieck GC: A Critical Evaluation of Current Concepts in Cerebral Palsy. Physiology (Bethesda) 2019, 34(3):216-229.
Knuesel I, Chicha L, Britschgi M, Schobel SA, Bodmer M, Hellings JA, Toovey S, Prinssen EP: Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol 2014, 10(11):643-660.
Jiang NM, Cowan M, Moonah SN, Petri WA, Jr.: The Impact of Systemic Inflammation on Neurodevelopment. Trends Mol Med 2018, 24(9):794-804.
Strle K, Zhou JH, Shen WH, Broussard SR, Johnson RW, Freund GG, Dantzer R, Kelley KW: Interleukin-10 in the brain. Crit Rev Immunol 2001, 21(5):427-449.
Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles KE, Tian S, Cardinale I, Chimenti S, Krueger JG: Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011, 131(3):677-687.
Liao W, Lin JX, Leonard WJ: Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy. Immunity 2013, 38(1):13-25.
Carlo WA, McDonald SA, Tyson JE, Stoll BJ, Ehrenkranz RA, Shankaran S, Goldberg RN, Das A, Schendel D, Thorsen P et al: Cytokines and neurodevelopmental outcomes in extremely low birth weight infants. J Pediatr 2011, 159(6):919-925 e913.
Kaukola T, Satyaraj E, Patel DD, Tchernev VT, Grimwade BG, Kingsmore SF, Koskela P, Tammela O, Vainionpaa L, Pihko H et al: Cerebral palsy is characterized by protein mediators in cord serum. Annals of Neurology 2004, 55(2):186-194.
Boyman O, Sprent J: The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012, 12(3):180-190.
Zelante T, Fric J, Wong AY, Ricciardi-Castagnoli P: Interleukin-2 production by dendritic cells and its immuno-regulatory functions. Front Immunol 2012, 3:161.
Arenas-Ramirez N, Woytschak J, Boyman O: Interleukin-2: Biology, Design and Application. Trends Immunol 2015, 36(12):763-777.
Malek TR, Castro I: Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity. Immunity 2010, 33(2):153-165.
Beck RD, Jr., King MA, Ha GK, Cushman JD, Huang Z, Petitto JM: IL-2 deficiency results in altered septal and hippocampal cytoarchitecture: relation to development and neurotrophins. J Neuroimmunol 2005, 160(1-2):146-153.
Beck RD, Jr., Wasserfall C, Ha GK, Cushman JD, Huang Z, Atkinson MA, Petitto JM: Changes in hippocampal IL-15, related cytokines, and neurogenesis in IL-2 deficient mice. Brain Res 2005, 1041(2):223-230.
Petitto JM, Cushman JD, Huang Z: Effects of Brain-Derived IL-2 Deficiency and the Development of Autoimmunity on Spatial Learning and Fear Conditioning. J Neurol Disord 2015, 3(1):196.

No competing interests reported.

Download PDF

Editorial decision: Major revision
12 Jul, 2022
Reviews received at journal
27 Jun, 2022
Reviewers agreed at journal
24 Jun, 2022
Reviewers invited by journal
20 Jun, 2022
Editor assigned by journal
20 Jun, 2022
Editor invited by journal
19 May, 2022
Submission checks completed at journal
19 May, 2022
First submitted to journal
14 May, 2022

You are reading this latest preprint version

An association study of IL2RA polymorphisms with cerebral palsy in a Chinese population

Status:

Version 1

Abstract

Background

Methods

Results

Conclusions

Background

Methods

Participants

CP diagnosis, classification and exclusion criteria

Genotyping and statistical analysis

Results

Overall analysis

Subgroup analysis

Discussion

Conclusion

Abbreviations

Declarations

References

Additional Declarations

Status:

Version 1